Kura Oncology and Kyowa Kirin announced that clinical data from the KOMET-007 trial, evaluating ziftomenib in combination with the standard chemotherapy regimen of cytarabine and daunorubicin (7+3) ...
Optimizing Blinatumomab Access for Low- and Middle-Income Countries: Feasibility of a Shortened, Vial-Sharing, Outpatient Approach for Pediatric ALL We retrospectively analyzed 473 adult patients with ...
Stocktwits on MSN
SLS stock hits 4-year high: BlackRock stake boost fuels buzz around looming AML trial readout
Other institutions, including Mariner and Ameritas Investment Partners, also increased exposure to the stock. ・Sellas said on Tuesday that its Phase 3 Regal AML study had reached 78 events as of May ...
At the European Hematology Association (EHA) 2025 Congress, Ashley Yocum, PhD, highlights how the Beat AML Master Trial advances safe, personalized treatment and expands targeted therapy options for ...
Revumenib demonstrates significant efficacy in R/R AML with NPM1m, KMT2Ar, and NUP98r, showing high response rates and tolerability. The AUGMENT-101 study reports a 26% CR/CRh rate in NPM1-mutated AML ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results